Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

NCT05111912 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of the experimental drug XW003 to the approved drug liraglutide on body weight in adults with obesity.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 206 people

Who can join Ages 18–70 · all sexes

Timeline Started 2021-11 · est. completion 2022-12

Where 1 site · Australia

What this study is testing ClinicalTrials.gov NCT05111912 ↗

Description as written by the study sponsor.

XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.

Treatments tested

XW003 also known as GLP-1 analogue Drug

XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.
Saxenda also known as GLP-1 analogue Drug

If a participant does not tolerate the recommended target dose of Saxenda group (e.g., 3.0 mg once daily), the participant may stay at the preceding highest tolerable dose (e.g., 2.4 mg once daily).

Main thing measured	Percentage change in participants body weight (%) from the Baseline
Sponsor	Sciwind Biosciences APAC CO Pty. Ltd.
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05111912 ↗